[1] 中华医学会感染病学分会, GRADE 中国中心. 中国乙型肝炎病毒母婴传播防治指南(2019 年版). 中华传染病杂志,2019,37:388-396.
[2] Zou H, Chen Y, Duan Z, et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat, 2012, 19:e18-e25.
[3] Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med, 2016, 374: 2324-2334.
[4] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J Hepatol, 2017,67:370-398.
[5] Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B:AASLD 2018 Hepatitis B Guidance. Hepatology, 2018, 67:1560-1599.
[6] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019 年版). 肝脏,2019,24:1335-1356.
[7] Sheng QJ, Wang SJ, Wu YY, et al. Hepatitis B virus sero-survey and awareness of mother-to-child transmission among pregnant women in Shenyang, China. Medicine, 2018, 97:e10931-e10935.
[8] 中华医学会肝病学分会. 感染乙型肝炎病毒的育龄女性临床管理共识. 临床肝胆病杂志, 2018, 34:1176-1180.
[9] Corbett AH, Kayira D, White NR, et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post- partum: Results of the BAN Study .Antivir Ther, 2014,19:587-595.
[10] 崔富强, 庄辉. 我国新生儿乙型肝炎母婴阻断成就和展望.中国病毒病杂志, 2019, 9:321-326. |
